• Skip to main content
  • Skip to primary sidebar

Biotech Briefings

  • Home
  • About
  • Editors
  • Topics
  • Subscribe
  • Home
  • About
  • Editors
  • Topics
  • Subscribe

What Life Sciences Companies Should Know About the New Trade Fraud Task Force

September 10, 2025 | Posted by Adam M. Smith; Samantha Sewall; Topic(s): Government Regulation; International Trade; Trends and Insights

On August 29, 2025, the Department of Justice (DOJ) launched the Trade Fraud Task Force that will coordinate efforts between DOJ’s Civil and Criminal Divisions and the Department of Homeland Security (DHS) to bring enforcement actions against importers who unlawfully evade tariffs and other customs duties, as well as against parties who unlawfully import prohibited goods.[1] This is the latest sign that, amid legal battles over the legality of President Trump’s tariffs, DOJ remains deeply committed to using all available legal tools to police customs and tariff compliance.  It is also the latest example of this Administration’s top-down approach to generating investigative targets.

As with previous actions, the announcement of the Trade Fraud Task Force underscores the importance for importers–particularly those touching tariff sensitive commodifies such as pharmaceuticals–to develop and maintain robust mechanisms to comply with customs requirements and duties.

Gibson Dunn’s False Claims Act and International Trade teams explain the details: Getting Serious About Tariff Evasion – New Trade Fraud Task Force Continues Trend of DOJ’s Top-Down Generation of Investigative Targets – Gibson Dunn

Share:

Primary Sidebar

Gibson Dunn Life Sciences
2025 Outlook Webcast Series
Capital Markets: Click here to view the video recording and program materials.
Royalty Finance: Click here to view the video recording and program materials.
Read ROYALTY REPORT here.

Topics

Capital Markets

Clinical Trials

CVR Spinoff

CVRs

Delaware Law

ECVC

False Claims Act

FDA

FDA Guidance

Government Regulation

International Trade

IPOs

License Agreements

M&A

Manufacturing

Reverse Mergers

Royalty Finance

SEC Disclosure

SEC Updates

Securities Litigation

Shareholder Activism

Tax

Trends and Insights

Editors

Rachel E. Baron

Branden C. Berns

Aaron K. Briggs

Jina L. Choi

Matt Donnelly

Gustav W. Eyler

Hui Fang

Carlo Felizardo

Mark Goldman

Bree Gong

Charlotte Jacobsen

Jin Hee Kim

Wynne Leahy

Jeff Lombard

Jane M. Love, Ph.D.

Mary Beth Maloney

Katlin McKelvie

James J. Moloney

Ryan A. Murr

Melanie E. Neary

John D.W. Partridge

Jonathan M. Phillips

Lindsey D. Schmidt

Samantha Sewall

Sam Shapiro

Eric B. Sloan

Adam M. Smith

Karen A. Spindler

Eric J. Stock

Xuan Hong Tran

Todd J. Trattner

Jessica Valenzuela

Lindsay Bernsen Wardlaw

Stephen Weissman

Kamia Williams

Useful Links

  • Gibson Dunn Website
  • Gibson Dunn Life Sciences Landing page
  • Securities Regulation and Corporate Governance Monitor
  • NVCA Model Legal Documents
  • Royalty Finance Tracker
  • Royalty Report: Royalty Finance Transactions in the Life Sciences 2020-2024
  • IPO Resource Center
  • IP Disputes and Litigation

Archives

Subscribe to Updates
RSS Feed
  • Privacy Statement
  • Cookie Notice
  • Contact Us
© 2025 Gibson, Dunn & Crutcher LLP. All rights reserved.